𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Carcinoma erysipeloides of the facial skin in a patient with metastatic breast cancer

✍ Scribed by R. Hinrichs; K. Kirchberg; J. Dissemond; J.D. Hoppe; P. Brenneisen; T. Krieg; K. Scharffetter-Kochanek

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
191 KB
Volume
141
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Predictors of skeletal complications in
Predictors of skeletal complications in patients with metastatic breast carcinoma
✍ Susan M. Domchek; Jerry Younger; Dianne M. Finkelstein; Michael V. Seiden πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 2 views

## Background: The high rate of incidence of skeletal complications in women with metastatic breast carcinoma appears to contribute significantly to their morbidity. although recent trials have demonstrated the efficacy of bisphosphonates in preventing skeletal complications in selected patients, t

Prognostic factors affecting adrenalecto
Prognostic factors affecting adrenalectomy in patients with metastatic cancer of the breast
✍ Mary Lou Schmidt; Takuma Nemoto; Thomas Dao; Irwin D. J. Bross πŸ“‚ Article πŸ“… 1971 πŸ› John Wiley and Sons 🌐 English βš– 485 KB πŸ‘ 3 views

The data presented were obtained in partial fulfillment of the requirements for the degree of Master of Science at the State University of R'ew \'ark at Buffalo.

Phase II study of ionidamine in patients
Phase II study of ionidamine in patients with metastatic breast cancer
✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi